Company intelligence / Profile preview

Aileron Pharmaceuticals

Austin, Texas, United Stateseconomictimes.indiatimes.com ↗

Ownership: Private
Employees: ~11
Development stage: Phase 1

Overview

The company has completed Phase 1b and Phase 2a clinical trials for LTI-01 in LPE patients, and LTI-03 is in Phase 1b clinical trial for IPF treatment[2]

Therapeutic areas: PulmonologyRare Diseases
Modalities: PeptidesProenzymes
Industry: Biotech

Drug pipeline

1 asset

ATSP-7041

Phase 1

Indications: Cancer

Beyond the preview

Go deeper on Aileron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aileron Pharmaceuticals.

Explore the full profile